Vibecotamab |
XmAb-14045 |
Phase 1 Clinical |
Xencor Inc |
Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute |
Details
|
ONO-4685 |
ONO-4685 |
Phase 1 Clinical |
Merus Nv |
Psoriasis; Lymphoma, T-Cell |
Details
|
GBR-1342 |
GBR-1342; ISB-1342 |
Phase 1 Clinical |
Glenmark Pharmaceuticals Ltd |
Multiple Myeloma |
Details
|
QLS-31905 |
QLS-31905 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
BS-006 |
BS-006 |
Phase 1 Clinical |
|
Solid tumours; Melanoma; Uterine Cervical Neoplasms |
Details
|
CCW-702 |
CCW-702 |
Phase 1 Clinical |
The Scripps Research Institute Inc, Abbvie Inc |
Prostatic Neoplasms |
Details
|
RG-6007 |
RG-6007 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Leukemia, Myeloid, Acute |
Details
|
JNJ-80948543 |
JNJ-80948543 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) |
|
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Solid tumours; Chondrosarcoma; Leukemia; Neoplasms; Hodgkin Disease; Neuroblastoma; Lymphoma |
Details
|
GEN-1047 |
GEN-1047 |
Phase 2 Clinical |
Genmab A/S |
Ovarian Neoplasms; Breast Neoplasms; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Plamotamab |
XmAb-13676 |
Phase 2 Clinical |
Xencor Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Pancreatic Neoplasms |
Details
|
RG-6234 |
RG-6234 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) |
|
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh |
Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation |
Details
|
JNJ-63898081 |
JNJ-8081; JNJ-63898081 |
Phase 1 Clinical |
Janssen Global Services Llc |
Neoplasms |
Details
|
WVT-078(Novartis Pharma) |
WVT-078 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
IBI-389 |
IBI-389 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
Imvotamab |
IGM-2323 |
Phase 2 Clinical |
Igm Biosciences Inc |
Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
Azintuxizumab |
TNB-383B; ABBV-383 |
Phase 2 Clinical |
Teneobio Inc, Abbvie Inc |
Multiple Myeloma |
Details
|
XmAb-819 |
XmAb-819 |
Phase 1 Clinical |
Xencor Inc |
Kidney Neoplasms; Carcinoma, Renal Cell |
Details
|
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
BC-3448 |
BC-3448; BC3448 |
Phase 1 Clinical |
Wuxi Zhikang Hongyi Biological Technology Co Ltd |
Solid tumours |
Details
|
EMB-06 |
EMB-06; EMB06 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Multiple Myeloma |
Details
|
PF-07062119 |
PF-07062119 |
Phase 1 Clinical |
Pfizer Pharmaceuticals Ltd (China) |
Stomach Neoplasms; Large intestine neoplasm; Adenocarcinoma; Gastrointestinal Neoplasms |
Details
|
A-319 |
A-319 |
Phase 1 Clinical |
Evive Biotech Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
GR-1901 |
GR1901; GR-1901 |
Phase 1 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
HPN-536 |
HPN-536 |
Phase 2 Clinical |
Harpoon Therapeutics |
Neoplasms |
Details
|
JNJ-70218902 |
JNJ-70218902 |
Phase 1 Clinical |
Janssen Global Services Llc |
Neoplasms |
Details
|
RO-7425781 |
RO-7425781 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
JNJ-63709178 |
JNJ-9178; CNTO-9958; JNJ-63709178 |
Phase 1 Clinical |
Janssen Global Services Llc, Genmab A/S |
Leukemia, Myeloid, Acute |
Details
|
Pavurutamab |
AMG-701 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
AMG-509 |
AMG-509 |
Phase 1 Clinical |
Amgen Inc, Xencor Inc |
Prostatic Neoplasms |
Details
|
hEGFRvIII-CD3 Bi-scFv |
|
Phase 1 Clinical |
Duke University |
Glioblastoma; Glioma |
Details
|
Emirodatamab |
AMG-427 |
Phase 1 Clinical |
Amgen Inc |
Leukemia, Myeloid, Acute |
Details
|
Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
Y-150; Y150 |
Phase 1 Clinical |
CSPC Pharmaceutical Group Ltd |
Multiple Myeloma |
Details
|
ASP-2138 |
ASP-2138 |
Phase 1 Clinical |
Astellas Pharma Global Development Inc, Xencor Inc |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) |
|
Phase 2 Clinical |
New York Medical College |
Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Lymphoma, Non-Hodgkin; Thrombocytopenia; Kostmann Syndrome; Anemia, Sickle Cell |
Details
|
A-337 |
A-337 |
Phase 1 Clinical |
Evive Biotech Ltd |
Neoplasms |
Details
|
TNB-486 |
TNB-486 |
Phase 1 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia) |
|
Phase 2 Clinical |
University Of Virginia |
Neuroblastoma |
Details
|
BI-765049 |
BI-765049; OBT-624 |
Phase 1 Clinical |
Boehringer Ingelheim Gmbh |
Head and Neck Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms |
Details
|
Anti-CD3-anti-HER2-activated T cells |
|
Phase 2 Clinical |
Transtarget |
Breast Neoplasms; Prostatic Neoplasms |
Details
|
Runimotamab |
BTRC-4017A; RG-6194 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms |
Details
|
Vixtimotamab |
T-564; AMV-564 |
Phase 1 Clinical |
Amphivena Therapeutics Inc |
Solid tumours; Myelodysplastic Syndromes |
Details
|
Anti-CD3/Anti-SLAMF7 Bispecific Antibody (University of Virginia) |
|
Phase 1 Clinical |
University Of Virginia |
Multiple Myeloma |
Details
|
GR-1803 |
GR-1803 |
Phase 1 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd |
Multiple Myeloma |
Details
|
K-193 |
K-193 |
Phase 1 Clinical |
Beijing Lvzhu Biological Technology Co Ltd |
Lymphoma, B-Cell |
Details
|
GNC-035 quadr-specific antibody(baili) |
GNC-035 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
Tidutamab |
XmAb-18087 |
Phase 2 Clinical |
Xencor Inc |
Carcinoma, Merkel Cell; Small Cell Lung Carcinoma |
Details
|
EX-101 |
EX-101; EX101 |
Phase 1 Clinical |
Guangzhou ASM Biomedical Technology Co Ltd |
Solid tumours |
Details
|
OBT620 |
OBT620 |
Phase 1 Clinical |
Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd |
Small Cell Lung Carcinoma |
Details
|
RO-7444973 |
RO-7444973 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms |
Details
|
TAK-186 |
EGFR x CD3 COBRA; MVC-101; TAK-186 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Anti-CD3 monoclonal antibody (Jinan Tiankang Biological Products) |
|
Phase 2 Clinical |
Jinan Tiankang Biological Products Co Ltd |
Anemia, Aplastic |
Details
|
EX-103 |
EX-103; EX103 |
Phase 1 Clinical |
Guangzhou ASM Biomedical Technology Co Ltd |
Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CX-904 |
CX-904 |
Phase 1 Clinical |
Amgen Inc, Cytomx Therapeutics Inc |
Solid tumours; Neoplasms |
Details
|
CN-201 |
CN-201 |
Phase 2 Clinical |
Tongrun Biomedicine (Shanghai) Co Ltd |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
Cibisatamab |
CEA-TCB; RG-7802; RO-6958688; CEA-CD3 TCB |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
JNJ-75348780 |
|
Phase 1 Clinical |
Janssen Research & Development Llc |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) |
|
Phase 2 Clinical |
University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune |
Breast Neoplasms |
Details
|
Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) |
LNF-1904 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
ARB-202 |
ARB-202 |
Phase 1 Clinical |
Arbele Corp |
Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Gastrointestinal Neoplasms |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
RG-6232 |
RG-6232 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Melanoma |
Details
|
CLN-049 |
CLN-049 |
Phase 1 Clinical |
University Of Tubingen, German Cancer Research Center (Dkfz) |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
PF-07260437(Pfizer) |
PF-07260437 |
Phase 1 Clinical |
Pfizer Inc |
Ovarian Neoplasms; Breast Neoplasms; Endometrial Neoplasms |
Details
|
BNT-142 |
BNT-142 |
Phase 2 Clinical |
Biontech Se |
Solid tumours |
Details
|
MGD-014 |
MGD-014 |
Phase 1 Clinical |
Macrogenics Inc |
HIV Infections |
Details
|
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center |
|
Phase 1 Clinical |
Roger Williams Medical Center |
Prostatic Neoplasms |
Details
|
Alnuctamab |
CC-93269; EM-901 |
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
TQB-2825 |
TQB-2825 |
Phase 1 Clinical |
Wuxi Biologics Co Ltd |
Hematologic Neoplasms; Neoplasms |
Details
|
SQZ-622(Novartis Pharma) |
SQZ-622 |
Phase 1 Clinical |
Novartis Pharma Ag |
Leukemia, Myeloid, Acute |
Details
|
ERY-974 |
ERY-974 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
CBA-1535 |
CBA-1535 |
Phase 1 Clinical |
Chiome Bioscience Inc |
Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung |
Details
|
TAK-280 |
MVC-280; TAK-280 |
Phase 2 Clinical |
Maverick Therapeutics Inc |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
RO-7428731 |
RO-7428731 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Glioblastoma |
Details
|
F-182112 |
F-182112; F182112 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
BC-004 |
BC-004 |
Phase 1 Clinical |
Shandong Buchang Pharmaceuticals Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
QLS-31904 |
QLS31904; QLS-31904 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
GNR-084 |
GNR-084 |
Phase 2 Clinical |
Generium Pharmaceuticals, Iontas |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Membrane bound ligand T-SIGn virus |
NG-348 |
Phase 1 Clinical |
|
Neoplasms |
Details
|
XmAb-18968 |
XmAb-18968 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Leukemia, Myeloid, Acute |
Details
|
Acapatamab |
AMG-160 |
Phase 2 Clinical |
Amgen Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) |
|
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
CC-312 |
CC-312 |
Phase 1 Clinical |
|
|
Details
|
M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
M-802 |
Phase 1 Clinical |
CSPC Pharmaceutical Group Ltd |
Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms |
Details
|
SMET-12 |
SMET-12 |
Phase 1 Clinical |
Zhejiang Shimai Pharmaceutical Co Ltd |
Solid tumours |
Details
|
REGN-5459 |
REGN-5459 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Multiple Myeloma; Renal Insufficiency, Chronic |
Details
|
CM-336(Connaught Biomedical Technology) |
CM-336 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Multiple Myeloma |
Details
|
JS-203 |
JS-203 |
Phase 1 Clinical |
|
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
RO-7293583 |
RO-7293583 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Skin Melanoma; Uveal melanoma; Melanoma |
Details
|
CM-350 |
CM-350 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Solid tumours |
Details
|
Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) |
|
Phase 2 Clinical |
Barbara Ann Karmanos Cancer Institute, University Of Virginia |
Glioblastoma; Pancreatic Neoplasms |
Details
|
APVO436 |
APVO-436 |
Phase 1 Clinical |
Aptevo |
Myeloproliferative Disorders; Leukemia, Myeloid, Acute |
Details
|
InHeAb-01 |
InHeAb-01; bsAB |
Clinical |
University Hospital Tuebingen |
Neoplasms |
Details
|
GB-261 |
GB-261 |
Phase 2 Clinical |
Genor Biopharma Co Ltd |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
XmAb-968 |
XmAb968 |
Phase 1 Clinical |
Xencor Inc |
Leukemia, Promyelocytic, Acute; Hematologic Neoplasms |
Details
|
JNJ-78278343 |
|
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms |
Details
|
JNJ-67571244 |
JNJ-67571244; JNJ-67371244; JNJ-1244 |
Phase 1 Clinical |
Johnson & Johnson |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
SAR-442257 |
SAR-442257 |
Phase 1 Clinical |
Sanofi |
Neoplasms |
Details
|
CD33xCD3 Bispecific Antibody (Y-mAbs Therapeutics) |
|
Phase 1 Clinical |
Y-Mabs Therapeutics Inc |
Leukemia, Myeloid, Acute |
Details
|
IMC-F106C |
IMC-F106C |
Phase 2 Clinical |
Immunocore Ltd |
Solid tumours |
Details
|
BI-764532 |
BI-764532 |
Phase 1 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Small Cell Lung Carcinoma; Neoplasms |
Details
|
JANX-007 |
JANX-007; PSMA-TRACTr |
Phase 1 Clinical |
Janux Therapeutics Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
MP0533 |
MP0533 |
Phase 2 Clinical |
Molecular Partners Ag |
Leukemia, Myeloid, Acute |
Details
|
Odronextamab |
REGN-1979 |
Phase 3 Clinical |
Regeneron Pharmaceuticals Inc |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
REGN-4336 |
REGN-4336 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
HPN-424 |
HPN-424 |
Phase 2 Clinical |
Harpoon Therapeutics |
Prostatic Neoplasms |
Details
|
JNJ-78306358 |
JNJ-78306358; JNJ-6358 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Neoplasms |
Details
|
1-A-46 |
BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 |
Phase 2 Clinical |
Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CC-1 |
CC-1 |
Phase 2 Clinical |
The University Of Tubingen, German Cancer Research Center (Dkfz) |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell |
Details
|
M-701 |
M-701 |
Phase 2 Clinical |
Cspc-Nbp Pharmaceutical Co Ltd |
Hydrothorax; Neoplasms; Ascites; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung |
Details
|
SAR-443216 |
SAR-443216 |
Phase 1 Clinical |
Sanofi |
Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
CLN-978 |
CLN-978 |
Phase 1 Clinical |
Adimab LLC |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
PIT-565 |
PIT-565 |
Phase 1 Clinical |
Novartis Pharma Ag |
Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin |
Details
|
YK-012 |
YK012 |
Phase 1 Clinical |
Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd |
Lymphoma, B-Cell |
Details
|
Emfizatamab |
GNC-038 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell |
Details
|
TNB-585 |
AMG-340; TNB-585 |
Phase 1 Clinical |
Teneobio Inc, Amgen Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
Cevostamab |
RG-6160; BFCR-4350A; RO-7187797 |
Phase 2 Clinical |
Genentech Inc |
Multiple Myeloma |
Details
|
RGV-004 |
RGV-004 |
Phase 1 Clinical |
Hangzhou Rongu Biotechnology Co Ltd |
Lymphoma, B-Cell |
Details
|
AMG-794 |
AMG-794 |
Phase 1 Clinical |
Amgen Inc |
Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung |
Details
|
Tepoditamab |
MCLA-117 |
Phase 1 Clinical |
Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc |
Leukemia, Myeloid, Acute |
Details
|
Ubamatamab |
REGN-4018 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
Details
|
NVG-111 |
NVG-111 |
Phase 2 Clinical |
NovalGen Ltd |
Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Linvoseltamab |
REGN-5458 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Multiple Myeloma; Renal Insufficiency, Chronic |
Details
|
CM-355(Beijing Tiannuo Jiancheng/Connaught Biomedical Technology) |
CM-355 |
Phase 2 Clinical |
Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd |
Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
MGD-024 |
MGD-024 |
Phase 1 Clinical |
Macrogenics Inc |
Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute |
Details
|
GEM3-PSCA |
GEM3-PSCA |
Phase 1 Clinical |
Gemoab Monoconals, Gcp Service International |
Kidney Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
AMG-199 |
AMG-199 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms |
Details
|
IMC-C103C |
IMC-C103C; RG-6290 |
Phase 2 Clinical |
Immunocore Ltd |
Solid tumours |
Details
|
AMG-562 |
AMG-562 |
Phase 1 Clinical |
Amgen Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular |
Details
|
Foralumab |
NI-0401/α-CD3; TZLS-401; NI-0401 |
Phase 2 Clinical |
Novimmune Sa, Bristol-Myers Squibb Company |
Respiratory Tract Infections; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Crohn Disease |
Details
|
Flotetuzumab |
S-80880; MGD-006; RES-234 |
Phase 2 Clinical |
Macrogenics Inc |
Leukemia; Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia, Hairy Cell; Hodgkin Disease; Mastocytosis, Systemic; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute |
Details
|
BCMA TriTAC |
HPN-217 |
Phase 1 Clinical |
Harpoon Therapeutics, Abbvie Inc |
Multiple Myeloma |
Details
|
Catumaxomab |
LP000 |
Phase 3 Clinical |
Trion Research, Neovii Biotech Gmbh |
Ovarian Neoplasms; Stomach Neoplasms; Carcinoma; Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Ascites; Urinary Bladder Neoplasms; Breast Neoplasms |
Details
|
MBS-303 |
MBS-303 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Lymphoma, B-Cell |
Details
|
EMB-07 |
EMB-07 |
Phase 1 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Adenocarcinoma of Lung; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Uterine Neoplasms |
Details
|
LBL-033 |
LBL-033 |
Phase 1 Clinical |
Nanjing Leads Biolabs Co Ltd |
Neoplasms |
Details
|
NG-641 |
NG-641; NG-aFAP; EnAd-FAP-Tac; EnAd-FAP-BiTE |
Phase 1 Clinical |
University Of Oxford, Akamis Bio Ltd |
Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis |
Details
|